- Home
- ACRS vs MDV Comparison
ACRS vs MDV Comparison
Compare ACRS & MDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- MDV
- Stock Information
- Founded
- ACRS 2012
- MDV 2015
- Country
- ACRS United States
- MDV United States
- Employees
- ACRS N/A
- MDV N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- MDV Transportation Services
- Sector
- ACRS Health Care
- MDV Consumer Discretionary
- Exchange
- ACRS Nasdaq
- MDV Nasdaq
- Market Cap
- ACRS 132.0M
- MDV 152.5M
- IPO Year
- ACRS 2015
- MDV 2022
- Fundamental
- Price
- ACRS $2.24
- MDV $14.55
- Analyst Decision
- ACRS Strong Buy
- MDV Strong Buy
- Analyst Count
- ACRS 5
- MDV 1
- Target Price
- ACRS $11.00
- MDV $18.00
- AVG Volume (30 Days)
- ACRS 656.6K
- MDV 33.8K
- Earning Date
- ACRS 03-04-2025
- MDV 03-04-2025
- Dividend Yield
- ACRS N/A
- MDV 7.94%
- EPS Growth
- ACRS N/A
- MDV N/A
- EPS
- ACRS N/A
- MDV N/A
- Revenue
- ACRS $27,079,000.00
- MDV $47,416,592.00
- Revenue This Year
- ACRS N/A
- MDV N/A
- Revenue Next Year
- ACRS N/A
- MDV $2.15
- P/E Ratio
- ACRS N/A
- MDV N/A
- Revenue Growth
- ACRS 26.35
- MDV N/A
- 52 Week Low
- ACRS $0.95
- MDV $13.69
- 52 Week High
- ACRS $5.17
- MDV $18.11
- Technical
- Relative Strength Index (RSI)
- ACRS 39.59
- MDV 42.36
- Support Level
- ACRS $2.11
- MDV $14.67
- Resistance Level
- ACRS $2.42
- MDV $15.22
- Average True Range (ATR)
- ACRS 0.15
- MDV 0.56
- MACD
- ACRS 0.00
- MDV -0.05
- Stochastic Oscillator
- ACRS 26.53
- MDV 8.11
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About MDV Modiv Industrial Inc. Class C
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.